The BCL2 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This heterogeneous pool contains cells with varied disruption events in the BCL2 gene, collectively abolishing functional BCL2 protein expression. The polyclonal format offers a robust loss-of-function model that mitigates clonal artifacts and better represents the genetic diversity encountered in tumor cell populations. It is suitable for dissecting BCL2-dependent apoptosis regulation in a lung cancer context without relying on single-cell-derived clones.
A-549 cells were originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma and display an adherent epithelial morphology. This well-characterized cell line serves as a widely accepted model for studying non-small cell lung cancer biology, including tumorigenesis, drug metabolism, and epithelial barrier function. A-549 cells harbor wild-type TP53 and express key components of the intrinsic apoptosis machinery, making them an ideal host for investigating the role of BCL2 in apoptosis resistance commonly observed in solid tumors.
BCL2 is an anti-apoptotic protein that binds and inhibits BAX and BAK, thereby blocking mitochondrial cytochrome c release. Its transcription is activated by STAT3, NF-??B, and CREB downstream of IL-3, IL-6, and PI3K-AKT/JAK-STAT signaling, and it is post-transcriptionally repressed by miR-15a and miR-16-1. Upon apoptotic signaling, BH3-only proteins (BID, BIM, PUMA, NOXA) displace BCL2 from BAX/BAK, permitting oligomerization, cytochrome c efflux, APAF-1-mediated caspase-9 activation, and executioner caspase-3 cleavage. BCL2 also engages BECN1 to influence autophagy. Thus, BCL2 disruption dismantles critical survival interactions, heightening apoptotic sensitivity.
Elimination of BCL2 in A-549 cells sensitizes this lung adenocarcinoma model to apoptosis induced by genotoxic stress, targeted agents, or withdrawal of survival factors. The knockout population provides a valuable platform to probe how loss of the BCL2 rheostat alters signal transduction through PI3K-AKT and JAK-STAT pathways, and how it may cooperate with p53 status to influence therapeutic response. Because BCL2 is frequently overexpressed in various cancers, this model facilitates the study of intrinsic and acquired drug resistance mechanisms, helping to validate BCL2 as a therapeutic target in a clinically relevant epithelial cancer background.
Researchers can use this product to dissect apoptotic signaling, evaluate BH3 mimetics and other pro-apoptotic agents, and conduct large-scale drug or RNAi screens. Standard assays include western blotting for BCL2 depletion, Annexin V/PI flow cytometry for apoptosis, caspase-3/7 activity assays, cytochrome c release measurements, MTT viability tests, and co-immunoprecipitation to study BCL2 interactomes. Gene interaction studies can map synthetic lethal partners and compensatory survival pathways. For further information, please contact Ascent Research.
